AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11135723
Drug: Sustained-release hydromorphone
RxNorm normalized name: hydromorphone Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release hydromorphone (8, 16, and 32 mg)
Trial: 11135723
Drug: Immediate-release hydromorphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release hydromorphone (8 mg)
Trial: 7857346
Drug: pidotimod 50
RxNorm normalized name: pidotimod
DrugBank: Pidotimod (DB11364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pidotimod 50 mg, 100 mg, 200 mg twice a day
Trial: 7857346
Drug: pidotimod (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pidotimod (any dosage)
Trial: 7857346
Drug: pidotimod 400
RxNorm normalized name: pidotimod 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pidotimod 400 mg/day
Trial: 2706957
Drug: 10 widely
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 widely used surfactants and 1 solubilizer applied in aqueous solutions of 12.5 millimoles/l for 45 min twice daily for 3 weeks
Trial: 21304253
Drug: Morning medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning medication (50 mg of naftopidil once a day after breakfast for 8 weeks)
Trial: 21304253
Drug: Evening medication
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evening medication (50 mg of naftopidil once a day after supper for 8 weeks)
Trial: 21304253
Drug: Morning medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning medication (50 mg of naftopidil)
Trial: 21304253
Drug: Evening medication
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evening medication (50 mg of naftopidil)
Trial: 19736473
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (FA), 5 mg/day
Trial: 19736473
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (FA), 5 mg/day + vitamin B12, 1 mg/day
Trial: 19736473
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (FA), 15 mg/day
Trial: 19736473
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (FA), 15 mg/day + vitamin B12, 1 mg/day
Trial: 11106014
Drug: Fluoride gel
RxNorm normalized name: Sodium Fluoride Gel
DrugBank: Sodium fluorophosphate (DB09484)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride gel only (Control)
Trial: 3335295
Drug: Colloidal bismuth
RxNorm normalized name: Colloidal bismuth subcitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloidal bismuth subcitrate, amoxicillin, and the combination of colloidal bismuth subcitrate and amoxicillin
Trial: 3335295
Drug: Amoxicillin monotherapy
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin monotherapy
Trial: 28302406
Drug: Microalgae oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microalgae oil (2.1 g DHA/d)
Trial: 21369788
Drug: Increased sunlight
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Increased sunlight exposure (additional 30‐40 min/day in the early morning) with calcium supplementation (600 mg/day)
Trial: 19576114
Drug: Standard dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosage targeting goal (SDTG) group - atorvastatin 10 mg/d
Trial: 19576114
Drug: Intensive dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive dosage targeting goal (IDTG) group - atorvastatin 20-80 mg/d
Trial: 19576114
Drug: Standard dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosage non-targeting goal (SDNTG) group - atorvastatin 10 mg/d without targeting goal
Trial: 19576114
Drug: All dosages
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All dosages of atorvastatin (10 mg, 20 mg, 40 mg, 80 mg)
Trial: 17767636
Drug: Propofol-ketamine (PK)
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol-ketamine (PK) - 1 mg x kg(‐1) ketamine + 1.2 mg x kg(‐1) propofol
Trial: 17767636
Drug: Propofol-fentanyl (PF)
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol-fentanyl (PF) - 1 microg x kg(‐1) fentanyl + 1.2 mg x kg(‐1) propofol
Trial: 14687871
Drug: Olanzapine (5-25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (5-25 mg/day)
Trial: 14687871
Drug: Clozapine (100-500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozapine (100-500 mg/day)
Trial: 12405466
Drug: Pilocarpine dissolved
RxNorm normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pilocarpine dissolved in artificial saliva administered in a mouth spray
Trial: 7821274
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g VGB
Trial: 7821274
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g VGB
Trial: 7821274
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g VGB
Trial: 96473
Drug: Haloperidol 5
RxNorm normalized name: haloperidol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 5 mg i.v. pretreatment
Trial: 30765242
Drug: MMRV (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMRV (two doses of combined measles-mumps-rubella-varicella vaccine)
Trial: 30765242
Drug: MMR +
RxNorm normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMR + V (one dose of live attenuated varicella vaccine after one dose of measles-mumps-rubella vaccine)
Trial: 30765242
Drug: MMR (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMR (two doses of measles-mumps-rubella vaccine)
Trial: 28676211
Drug: Bevacizumab added
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab added to pemetrexed/cisplatin (PC) chemotherapy
Trial: 28676211
Drug: Pemetrexed/cisplatin (PC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed/cisplatin (PC) chemotherapy alone
Trial: 24200199
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of Bifilact(®) probiotics (1.3 billion CFU, twice a day)
Trial: 24200199
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of Bifilact(®) probiotics (1.3 billion CFU, twice a day) in patients who had surgery
Trial: 22596211
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol (CZP) 200 mg + Methotrexate (MTX)
Trial: 19058924
Drug: Non-active control
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-active control condition (e.g., placebo or attention-only control)
Trial: 19058924
Drug: Validated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Validated treatment via a different modality
Trial: 19058924
Drug: Tests of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tests of the new treatment as an add-on to standard treatment
Trial: 19058924
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of dose-response design
Trial: 19058924
Drug: Provision of
RxNorm normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provision of optimal therapy to those who fail during the study
Trial: 19058924
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of the experimental treatment vs. standard treatment
Trial: 17160407
Drug: Exenatide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide (5 microg twice daily for 4 weeks, then 10 microg thereafter)
Trial: 456272
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 0.25 mg g-strophanthin
Trial: 456272
Drug: Sublingual administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual administration of 6.0 mg g-strophanthin
Trial: 30674348
Drug: Online self-help
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Online self-help program ('Restart') based on cognitive behavioral therapy (CBT)
Trial: 23392147
Drug: Sugared chewing
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugared chewing gum (Gum) - instructed to chew 3 times daily for 45 minutes each time for 7 days postoperatively
Trial: 21248332
Drug: TS-11-MG vaccine
RxNorm normalized name: L1 protein, human papillomavirus type 11 vaccine / L1 protein, human papillomavirus type 16 vaccine / L1 protein, human papillomavirus type 18 vaccine / L1 protein, human papillomavirus type 6 vaccine Prefilled Syringe [Gardasil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TS-11-MG vaccine
Trial: 21248332
Drug: Bacterin +
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bacterin + TS-11-MG combined
Trial: 19283449
Drug: Adjusted body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted body weight (ABW) dosing of enoxaparin
Trial: 19283449
Drug: Standard dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosing of enoxaparin
Trial: 16211988
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 1200 mg orally 3 hours before and 3 hours after the procedure
Trial: 9856543
Drug: Caffeine ingestion
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine ingestion (10 mg x kg(‐1))
Trial: 8929239
Drug: GE uncrushed
RxNorm normalized name: 18F-GE-180
DrugBank: Flutriciclamide F-18 (DB15380)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GE uncrushed (120 mg myrtol standardized)
Trial: 8929239
Drug: GE crushed
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GE crushed (120 mg myrtol standardized)
Trial: 8929239
Drug: GF uncrushed
RxNorm normalized name: Codar GF
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GF uncrushed (300 mg myrtol standardized)
Trial: 8929239
Drug: GF crushed
RxNorm normalized name: Codar GF
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GF crushed (300 mg myrtol standardized)
Trial: 2191783
Drug: Warfarin administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin administered simultaneously with heparin infusion
Trial: 2191783
Drug: Heparin without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin without warfarin therapy
Trial: 419977
Drug: Pilocarpine eyedrops
RxNorm normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pilocarpine eyedrops (2% solution four times daily)
Trial: 25389283
Drug: ZRS ≥2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZRS ≥2 and NT-proBNP ≥200 pg/mL
Trial: 22996693
Drug: CXCR1/2 allosteric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CXCR1/2 allosteric inhibitor reparixin
Trial: 12017346
Drug: Eletriptan (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eletriptan (10 to 120 mg)
Trial: 12017346
Drug: Eletriptan (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eletriptan (30 to 90 mg)
Trial: 1751651
Drug: Chlorazepam as
RxNorm normalized name: Clonazepam
DrugBank: Clonazepam (DB01068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorazepam as oral premedication (n = 25)
Trial: 30195882
Drug: Garlic supplement
RxNorm normalized name: Garlic 300 MG Oral Capsule [GARLIC SUPPLEMENT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garlic supplement (1000 mg, twice daily for 12 weeks)
Trial: 22169398
Drug: Recommended fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommended fluid intake (mean amount 2427 ml)
Trial: 22169398
Drug: Low fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low fluid intake (mean amount 1625 ml)
Trial: 19765674
Drug: Citalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (20 mg/day for 4 weeks, then 40 mg/day for 4 weeks)
Trial: 12060531
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral administration of leflunomide (20 mg, 40 mg, 60 mg)
Trial: 12060531
Drug: Repeated oral
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated oral administration of leflunomide (20 mg/d for 30 days)
Trial: 8578014
Drug: Aerosol inhalation
RxNorm normalized name: Albuterol Inhalation Aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosol inhalation of fenoterol
Trial: 8578014
Drug: Intravenous route
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous route of fenoterol
Trial: 8578014
Drug: Metered dose
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metered dose inhalers (MDI) inhalation of fenoterol
Trial: 8578014
Drug: Aerosol inhalation
RxNorm normalized name: Albuterol Inhalation Aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosol inhalation of 200 micrograms of fenoterol
Trial: 4054195
Drug: atenolol 100
RxNorm normalized name: atenolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atenolol 100 mg once-daily
Trial: 4054195
Drug: pindolol 20
RxNorm normalized name: pindolol 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pindolol 20 mg slow release (SR) once-daily
Trial: 27117853
Drug: Resistant Glucan
RxNorm normalized name: BETA GLUCAN
DrugBank: Yeast beta-D-glucan (DB19271)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistant Glucan Mixture (RGM) 13.2 g/d
Trial: 27117853
Drug: Resistant Glucan
RxNorm normalized name: BETA GLUCAN
DrugBank: Yeast beta-D-glucan (DB19271)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistant Glucan Mixture (RGM) 6.6 g/d
Trial: 27117853
Drug: Resistant Glucan
RxNorm normalized name: BETA GLUCAN
DrugBank: Yeast beta-D-glucan (DB19271)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistant Glucan Mixture (RGM) 3.3 g/d
Trial: 26307122
Drug: Supportive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive therapy for proximal plantar fasciitis (type of foot support not specified)
Trial: 23279560
Drug: Contingency management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contingency management (CM) with escalating vouchers for on-time alcohol-negative tests (n-BrAC; <0.02 g/dl)
Trial: 21700935
Drug: Group 3b
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 3b (eGFR 30.0 to 44.9 mL/min/1.73 m²)
Trial: 21700935
Drug: Group 3a
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 3a (eGFR 45.0 to 59.9 mL/min/1.73 m²)
Trial: 21700935
Drug: Group 2
RxNorm normalized name: Chlamydophila psittaci biogroup 2 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2 (eGFR 60.0 to 89.9 mL/min/1.73 m²)
Trial: 21700935
Drug: Group 1
RxNorm normalized name: Chlamydophila psittaci biogroup 1 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 (eGFR ≥ 90.0 mL/min/1.73 m²)
Trial: 19086960
Drug: mesalamine foam
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mesalamine foam 1 g/80 mL/day
Trial: 19086960
Drug: mesalamine liquid
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mesalamine liquid enema 1 g/100 mL/day
Trial: 14996064
Drug: Chloroatranol 5
RxNorm normalized name: chlorobutanol 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroatranol 5 p.p.m. solution applied for 14 days
Trial: 14996064
Drug: Chloroatranol 25
RxNorm normalized name: Chlorobutanol
DrugBank: Chlorobutanol (DB11386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroatranol 25 p.p.m. solution applied for additional 14 days if no reaction to 5 p.p.m.
Trial: 14996064
Drug: Patch testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch testing with chloroatranol
Trial: 10723239
Drug: Reduced dose
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced dose (S-1 group, n = 13; BHAC 150 mg/m2 1-7 day, DNR 30 mg/m2 1-3 day, 6MP 70 mg/m2 1-7 day)
Trial: 10723239
Drug: Conventional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dose (S-2 group, n = 16; BHAC 200 mg/m2 1-7 day, DNR 40 mg/m2 1-3 day, 6MP 70 mg/m2 1-7 day)
Trial: 3068400
Drug: Streptokinase treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptokinase treatment (1,000,000 units over 60 min)
Trial: 3068400
Drug: Intracoronary streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary streptokinase administration (120,000‐180,000 units over 60‐90 min)
Trial: 3068400
Drug: Intravenous and
RxNorm normalized name: immune globulin intravenous and subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous and intracoronary routes of administration
Trial: 25420736
Drug: 4 L
RxNorm normalized name: PEG-4 laurate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 L PEG + bisacodyl 10 mg
Trial: 25420736
Drug: PEG only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG only group (4 L PEG)
Trial: 23011562
Drug: Phenylephrine bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine bolus (120 μg)
Trial: 23011562
Drug: Phenylephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine infusion (120 μg/min)
Trial: 2544119
Drug: Etomidate infusion
RxNorm normalized name: Etomidate
DrugBank: Etomidate (DB00292)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etomidate infusion (16.8 +/- 3.0 mg.kg‐1.min‐1)
Trial: 25854635
Drug: Levetiracetam 500
RxNorm normalized name: levetiracetam 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam 500 mg/day
Trial: 11823112
Drug: Levetiracetam 2000
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam 2000 mg/day
Trial: 21863617
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of ephedrine (50 mg/500 ml of Ringer solution)
Trial: 21863617
Drug: Preoperative hydration
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative hydration with 20 ml/kg of Ringer solution
Trial: 21863617
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of ephedrine
Trial: 11564387
Drug: Propafenone (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone (mean daily dose 13 +/- 1.5 mg/kg)
Trial: 11564387
Drug: Sotalol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotalol (mean daily dose 3 +/- 0.4 mg/kg)
Trial: 25747197
Drug: Trebananib 10
RxNorm normalized name: Trebananib
DrugBank: Trebananib (DB12056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trebananib 10 mg/kg once weekly plus paclitaxel and bevacizumab (Arm A)
Trial: 25747197
Drug: Trebananib 3
RxNorm normalized name: Trebananib
DrugBank: Trebananib (DB12056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trebananib 3 mg/kg once weekly plus paclitaxel and bevacizumab (Arm B)
Trial: 25747197
Drug: Open-label trebananib
RxNorm normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label trebananib 10 mg/kg once weekly plus paclitaxel (Arm D)
Trial: 25747197
Drug: Open-label trebananib
RxNorm normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label trebananib 10 mg/kg once weekly (Arm D) with high exposure
Trial: 25747197
Drug: Open-label trebananib
RxNorm normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label trebananib 10 mg/kg once weekly (Arm D) with low exposure
Trial: 23167499
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy exercises
Trial: 20112576
Drug: Chinese herbs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbs promoting blood circulation and removing blood stasis (Caesalpinia Sappan 10 g, Ligusticum Chuanxiong 6 g, Frankincense 6 g, Angelica 10 g, Safflower 6 g, Myrrh 6 g, Ground Beetle 10 g, Araliaceae 3 g, Radix Paeoniae Rubra 10 g, Pericarpium Citri Reticulatae 5 g, Lawn Pennywort Herb 15 g, Manis Pentadactyla 10 g, Corydalis Yanhusuo 10 g, Rhizoma Drynariae 15 g) taken orally for 10 days, and external application of traditional medicine for fuming and washing limbs twice daily.